Risk for Incident Atrial Fibrillation in Patients Who Receive Antihypertensive Drugs

Schaer, Beat; Schneider, Cornelia; Jick, Susan S.; Conen, David; Oßwald, Stefan; Meier, Christoph

doi:10.7326/0003-4819-152-2-201001190-00005

Cited by 92 publications

(59 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, a nested case-control study in UK also demonstrated that treatment with ACEIs-based and ARBs-based regimen was associated with a 25 --29% reduction in AF compared with calcium channel blockers-based regimen. 49 Several meta-analyses 30 have been performed to investigate the effects of ACEIs and ARBs for AF prevention in patients with different cardiovascular diseases. These analyses mainly included clinical trials as mentioned above and most of them did not show significant reduction of AF with ACEIs and ARBs for primary prevention of AF.…”

Section: Raas Activationmentioning

confidence: 99%

Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications

Yiu

Siu

et al. 2011

J Hum Hypertens

View full text Add to dashboard Cite

Hypertension is one of the most important risk factors associated with atrial fibrillation (AF) and increased the risk of cardiovascular events in patients with AF. However, the pathophysiological link between hypertension and AF is unclear. Nevertheless, this can be explained by the hemodynamic changes of the left atrium secondary to long standing hypertension, resulting in elevated left atrium pressure and subsequently left atrial enlargement. Moreover, the activation of renin --angiotensin --aldosterone system (RAAS) activation in patients with hypertension induces left atrial fibrosis and conduction block in the left atrium, resulting in the development of AF. Accordingly, recent studies have shown that effective blockage of RAAS by angiotensin converting enzyme inhibitors or angiotensin receptor antagonist may be effective in both primary and secondary prevention of AF in patients with hypertension, although with controversies. In addition, optimal antithrombotic therapy, blood pressure control as well as rate control for AF are key to the management of patients with AF. 1,2 Both hypertension 3 and AF 4 have increased frequency with the ageing population worldwide, and are associated with increased cardiovascular events. They are important risk factors for stroke, heart failure and overall mortality. 5 --7 On the other hand, hypertension is one of the important risk factors for the occurrence of AF, 8 and increased the risk of stroke and cardiovascular mortality in patients with AF.9,10 Compare with other risk factors for AF, hypertension appears to be responsible for more AF than any other risk factor because of its high prevalence. However, the pathophysiological link between AF and hypertension remains unclear. Moreover, it is also unclear whether treatment of hypertension prevents AF or reduces the risk of AF related complications. The purpose of this article is to review the epidemiology, underlying mechanisms and therapeutic implications of AF in hypertensive patients. A systematic literature search for full-text papers in the English language was performed using MEDLINE, Embase and the Cochrane library through to July 2011. In the search phrases used, the following terms were used: 'atrial fibrillation', 'hypertension', 'epidemiology', 'pathophysiology' and 'treatment'. Papers selected and cited in this review were based on the authors' view on the relevance to the manuscript. In addition, abstracts from international cardiovascular meetings were studied to identify unpublished studies.

show abstract

Section: Raas Activationmentioning

confidence: 99%

Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications

Yiu

Siu

et al. 2011

J Hum Hypertens

View full text Add to dashboard Cite

show abstract

“…An RCT of 200 patients undergoing cardiac surgery showed atorvastatin decreased the incidence of postoperative AF by 61%; 44 a smaller trial also found this after electrical cardioversion, 45 but another found that pravastatin did not reduce AF recurrence. 46 36 The rate of acute recurrence of AF was lower in a RAAS group compared to controls (17% versus 31%, P = 0.026) in patients with AF scheduled for electric cardioversion. 48 Bisphosphonates Bisphosphonate use (specifically zoledronate and alendronate) has been reported as a risk factor for AF in women.…”

Section: Beta-2 Agonistsmentioning

confidence: 95%

Predictors of incident atrial fibrillation and influence of medications: a retrospective case–control study

2011

View full text Add to dashboard Cite

“…Это предположение косвенно подтверждается результатами анализа базы данных по общей практике в Великобритании, содержащей более 5 миллионов историй болезни. Данный анализ показал, что применение ингибиторов АПФ и блокато-ров рецепторов ангиотензина сопровождалось более низким риском фибрилляции предсердий, чем лечение антагонистами кальция [579]. То же самое было пока-зано для бета-блокаторов при сердечной недостаточно-сти.…”

Section: сердечная недостаточностьunclassified

2013 Esh/Esc Guidelines for the Management of Arterial Hypertension

Mancia

Fagard²,

Redón³

et al. 2014

Russ J Cardiol

View full text Add to dashboard Cite

Авторы/члены рабочей группы: Giuseppe Mancia (сопредседатель; италия)*, Robert Fagard (сопредседатель; бельгия)*, Krzysztof Narkiewicz (координатор секции, Польша), Josep Redón (координатор секции; испания), Alberto Zanchetti (координатор секции, италия), Michael Böhm

show abstract

Risk for Incident Atrial Fibrillation in Patients Who Receive Antihypertensive Drugs

Abstract: None.

Cited by 92 publications

References 32 publications

Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications

Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications

Predictors of incident atrial fibrillation and influence of medications: a retrospective case–control study

2013 Esh/Esc Guidelines for the Management of Arterial Hypertension

Contact Info

Product

Resources

About